Such tests indicate whether a person had an immune response to the virus, which could aid infection tracking and identifying individuals with immunity.
In announcing a national emergency on Friday, Trump paraded out executives from the private sector as the administration tries to increase testing capacity
Firms like LabCorp, Quest, and BioReference have launched tests but a lack of clarity around demand presents challenges for assessing what capacity is needed.
LabCorp's test is being made available pursuant to FDA guidance that allows high-complexity, CLIA-certified labs to perform their own tests for SARS-CoV-2.
Opko recorded $177.9 million in service revenues, $32 million in product revenues, and $14.4 million from licensing and the transfer of intellectual property revenues.
